Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab)
*DEGEVMA is now FDA-approved across all indications of the reference product, Xgeva (denosumab), to help prevent bone complications in adults with a
